Camurus AB (CAMRF) reports a 52% revenue increase, strategic licensing with Eli Lilly, and EU approval of Oczyesa, despite currency challenges and market hurdles.

Camurus AB reported its second-quarter earnings for 2025, revealing a robust financial performance with earnings per share (EPS) of 4.08, significantly surpassing the forecasted 3.27. The company ...

"Successful second quarter for Camurus" Summary second quarter 2025 April - June Total revenues grew 52% (65% at CER1) to SEK 676 (445) million Sales of Buvidal® increased 17% (26% at CER1) to SEK ...

Camurus (NASDAQ STO: CAMX) today announced that the European Commission (EC) has granted Oczyesa®, octreotide subcutaneous depot, marketing authorization* for the maintenance treatment in adult ...

Camurus (NASDAQ STO: CAMX) today announced that the European Commission (EC) has granted Oczyesa®, octreotide subcutaneous depot, marketing authorization* for the maintenance treatment in adult ...

Camurus, an international, science-led biopharmaceutical company, announced that the European Commission (EC) has granted Oczyesa, octreotide subcutaneous depot, marketing authorization for the ...